Jump to content

Edible algae vaccine

From Wikipedia, the free encyclopedia
(Redirected from Edible Algae Vaccines)
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Edible algae based vaccination is a vaccination strategy under preliminary research to combine a genetically engineered sub-unit vaccine and an immunologic adjuvant into Chlamydomonas reinhardtii microalgae. Microalgae can be freeze-dried and administered orally.[1] While spirulina is accepted as safe to consume,[2] edible algal vaccines remain under basic research with unconfirmed safety and efficacy as of 2018.[3]

In 2003, the first documented algal-based vaccine antigen was reported, consisting of a foot-and-mouth disease antigen complexed with the cholera toxin subunit B, which delivered the antigen to digestion mucosal surfaces in mice. The vaccine was grown in C. reinhardtii algae and provided oral vaccination in mice, but was hindered by low vaccine antigen expression levels.[4]

Proteins expressed inside the chloroplast of algae (the most common site of genetic engineering and protein production) do not undergo glycosylation, a form of posttranslational modification. Glycosylation of proteins that are not naturally modified like the malaria vaccine candidate pfs25 can occur in common expression systems like yeast.[5]

Notes

  1. ^ Specht 2014, p.1
  2. ^ FDA 2002
  3. ^ Specht 2014, p.3
  4. ^ Specht 2014, p.2
  5. ^ Gregory 2012, p.1

References

  • U.S. Food and Drug Administration (2002) GRAS Notification for Spirulina Microalgae
  • Specht, Elizabeth A.; Mayfield, Stephen P. (2014). "Algae-based oral recombinant vaccines". Frontiers in Microbiology. 5: 60. doi:10.3389/fmicb.2014.00060. PMC 3925837. PMID 24596570.
  • Rasala, Beth A.; Muto, Machiko; Lee, Philip A.; Jager, Michal; Cardoso, Rosa M.F.; Behnke, Craig A.; Kirk, Peter; Hokanson, Craig A.; Crea, Roberto; Mendez, Michael; Mayfield, Stephen P. (2010). "Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtii". Plant Biotechnology Journal. 8 (6): 719–733. doi:10.1111/j.1467-7652.2010.00503.x. PMC 2918638. PMID 20230484.
  • Shimp, Richard L.; Rowe, Christopher; Reiter, Karine; Chen, Beth; Nguyen, Vu; Aebig, Joan; Rausch, Kelly M.; Kumar, Krishan; Wu, Yimin; Jin, Albert J.; Jones, David S.; Narum, David L. (2013). "Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle". Vaccine. 31 (28): 2954–2962. doi:10.1016/j.vaccine.2013.04.034. PMC 3683851. PMID 23623858.
  • Gregory, James A.; Li, Fengwu; Tomosada, Lauren M.; Cox, Chesa J.; Topol, Aaron B.; Vinetz, Joseph M.; Mayfield, Stephen; Hviid, Lars (2012). "Algae-Produced Pfs25 Elicits Antibodies That Inhibit Malaria Transmission". PLOS ONE. 7 (5): e37179. Bibcode:2012PLoSO...737179G. doi:10.1371/journal.pone.0037179. PMC 3353897. PMID 22615931.